SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-072534
Filing Date
2024-06-12
Accepted
2024-06-12 17:01:06
Documents
12
Period of Report
2024-06-06
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20240606.htm   iXBRL 8-K 123299
2 EX-3 tcrt-ex3.htm EX-3 13345
  Complete submission text file 0000950170-24-072534.txt   269088

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20240606.xsd EX-101.SCH 32035
15 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20240606_htm.xml XML 4891
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 241039118
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)